Core Insights - Boundless Bio has decided not to advance BBI-825 into the Part 2 portion of the STARMAP clinical trial due to preliminary pharmacokinetic data and increasing development costs in the competitive landscape of BRAF and KRAS-mutated cancer treatment [2][5][6] - The company is focusing resources on BBI-355, which is on track for initial clinical proof-of-concept data in the second half of 2025, and a third ecDTx program, with a development candidate nomination expected by mid-2025 [3][5][6] - Leadership changes include the departure of Klaus Wagner, M.D., Ph.D., and Neil Abdollahian, with James L. Freddo, M.D., stepping in as Interim Chief Medical Officer [4][6] Pipeline Updates - BBI-355 is currently in a Phase 1/2 POTENTIATE clinical trial, targeting oncogene-amplified solid tumors, with preliminary clinical data expected in the second half of 2025 [3][5] - The decision not to advance BBI-825 was based on a lack of dose-proportional exposure observed in the trial and the complexities of the treatment landscape [3][5] - The third ecDTx program is progressing, targeting a kinesin essential for ecDNA segregation, with an IND application expected in the first half of 2026 [3][5] Leadership Transitions - Klaus Wagner, M.D., Ph.D., Chief Medical Officer, and Neil Abdollahian, Chief Business Officer, will leave the company, with James L. Freddo, M.D., taking over as Interim CMO [4][6] - Dr. Freddo has extensive experience in clinical leadership within biopharmaceutical companies [4]
Boundless Bio Announces Pipeline and Leadership Updates